# A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

> **NCT07137338** · PHASE1 · RECRUITING · sponsor: **Rocket Pharmaceuticals Inc.** · enrollment: 8 (estimated)

## Conditions studied

- Dilated Cardiomyopathy (DCM)

## Interventions

- **GENETIC:** RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

## Key facts

- **NCT ID:** NCT07137338
- **Lead sponsor:** Rocket Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07137338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07137338, "A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07137338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*